

Treatment strategy for synchronous metastases of colorectal cancer: is hepatic resection after an observation interval appropriate?

Yasuhiro Shimizu · Kenzo Yasui · Tsuyoshi Sano ·
Takashi Hirai · Yukihide Kanemitsu · Koji Komori ·
Tomoyuki Kato

Received: 9 June 2006 / Accepted: 11 January 2007 / Published online: 9 February 2007
© Springer-Verlag 2007

Abstract

Background In cases of synchronous colorectal hepatic metastases, the primary colorectal cancer strongly influences on the metastases. Our treatment policy has been to conduct hepatic resection for the metastases at an interval of 3 months after colorectal resection. We examined the appropriateness of interval hepatic resection for synchronous hepatic metastasis.

Materials and methods The subjects were 164 patients who underwent resection of hepatic metastasis of colorectal cancer (synchronous, 70 patients; metachronous, 94 patients). Background factors for hepatic metastasis and postoperative results were compared for synchronous and metachronous cases.

Results The cumulative survival rate for 164 patients at 3, 5, and 10 years postoperatively was 71.9%, 51.8%, and 36.6%, and the post-resection recurrence rate in remnant livers was 26.8%. Interval resection for synchronous hepatic metastases was conducted in 49 cases after a mean interval of 131 days. No difference was seen in postoperative outcome between synchronous and metachronous cases.

Conclusion The outcome was similarly favorable in cases of synchronous hepatic metastasis and in cases of metachronous metastasis. Delaying resection allows accurate understanding of the number and location of hepatic

metastases, and is beneficial in determining candidates for surgery and in selecting surgical procedure.

Keywords Hepatic metastasis of colorectal cancer · Synchronous hepatic metastasis · Interval hepatic resection

Introduction

In cases of colorectal cancer with simultaneous hepatic metastasis, the influence of the primary colorectal cancer is stronger than in cases with metachronous metastasis, so the possibility of occult hepatic metastases must be kept in mind. For this reason, the treatment strategies considered in cases of synchronous metastases differ from those in cases of metachronous metastases. Since 1983, the basic policy at our hospital for treating colorectal cancer with synchronous hepatic metastasis has been to resect the primary colorectal cancer, followed, if necessary, by resection of the hepatic metastasis after an observation interval of 3 months. In the present study, we investigated the validity of interval hepatic resection for synchronous hepatic metastases.

Materials and methods

Between January 1983 and December 2003, 223 patients underwent resection at our hospital for colorectal cancer with hepatic metastasis. The subjects for the present study were 164 of these patients who underwent curative resection and had no extrahepatic metastases or recurrences at the time of hepatic resection. The treatment results after hepatic resection in these patients (70 synchronous and 94 metachronous cases) were investigated. A comparison was

Y. Shimizu (✉) · K. Yasui · T. Sano · T. Hirai · Y. Kanemitsu ·
K. Komori · T. Kato
Department of Gastroenterological Surgery,
Aichi Cancer Center Hospital,
Kanokoden 1-1, Chikusa-ku,
Nagoya 464-8681, Japan
e-mail: yshimizu@aichi-cc.jp

made of surgical procedure, number of metastases, presence or absence of macroscopic invasive factors in the vicinity of the metastatic foci (vascular infiltration, bile duct invasion, direct invasion of adjacent viscera, minute satellite, hepatic lymph node metastasis) [1], maximum diameter of hepatic metastatic foci, recurrence in remnant liver, and outcome. Synchronous hepatic metastasis was defined in this study as hepatic metastasis discovered within 6 months after the colorectal operation.

In the statistical analysis, the *t* test or χ^2 test were used for comparisons between two groups, the Cox proportional hazard model was used for survival analysis, and the logrank test was used for survival rate. A *p* value of less than 0.05 was considered to indicate a significant difference.

Results

The hepatic resection procedure in the 164 cases was anatomical resection based on hemihepatectomy in 129 cases (78.7%), and partial resection in 35 cases (21.3%). Multivariate analysis was conducted for surgical procedure, metastasis period, number of metastases (single or multiple), presence or absence of invasive factors, and maximum tumor diameter. The results indicated that partial resection, lack of invasive factors, and small tumor diameter were associated with good outcomes. Metastatic period and single or multiple metastases were not significant prognostic factors. A multivariate analysis was conducted for the three factors that were significant in the univariate analysis, and tumor size was shown to be a significant independent prognostic factor (Table 1).

After hepatic resection, recurrence was seen in the remnant liver in 44 cases (26.8%), and the 3-, 5-, and 10-year cumulative survival rates were 71.9, 51.8, and 36.3%, respectively (Fig. 1).

The treatment outcomes in the 70 synchronous cases and 94 metachronous cases were compared. In the 70 synchro-




Fig. 1 Postoperative cumulative survival rate in 164 liver metastasis resection patients

nous cases, the hepatic resection was conducted simultaneously with the colorectal resection in 21 cases (30.0%) and after an interval in 49 cases (70.0%). The interval from the colorectal surgery until the liver resection was 34–361 days (mean 131 days, median 104 days).

No significant difference was found in the maximum diameter of the liver metastases between the two groups, with a mean of 4.5 cm in the synchronous group and 4.9 cm in the metachronous group. The mean number of metastases was greater in the synchronous group (2.2) than in the metachronous group (1.6). Partial resections were conducted in 22 of 70 (31.4%) patients in the synchronous group, which was significantly greater than the 13 of 94 (13.8%) in the metachronous group. Invasive factors were present in 17 (27.9%) synchronous cases and 40 (47.1%) metachronous cases, so a greater proportion of the synchronous cases had no invasive factors (Table 2).

After hepatic resection, recurrence in the remnant liver was seen in 22 of 70 (31.4%) synchronous cases and 22 of 94 (23.4%) metachronous cases. This difference was not significant ($p=0.3325$). The 3-, 5-, and 10-year postoperative survival rates were 75.0, 55.1, and 34.4% in synchronous cases, and 69.5, 49.1, and 37.3% in metachronous

Table 1 Survival analysis for 164 liver metastasis resections

	Relative risk	95% Lower limit	95% Upper limit	<i>p</i> value
Univariate analysis				
Procedure (anatomical resection/partial resection)	1.845:1.00	1.021	3.336	0.0426
Metastasis period (metachronous/synchronous)	1.077:1.00	0.698	1.663	0.7376
No. metastases (multiple/single)	0.777:1.00	0.502	1.202	0.2576
Invasive factors (no/yes)	0.504:1.00	0.323	0.785	0.0026
Tumor diameter	1.121	1.076	1.171	<0.0001
Multivariate analysis				
Procedure (anatomical resection/partial resection)	1.181:1.00	0.546	2.557	0.6722
Invasive factors (no/yes)	0.686:1.00	0.421	1.120	0.1320
Tumor diameter	1.099	1.045	1.155	0.0002

Table 2 Background factors for synchronous and metachronous metastases

	Synchronous 70 patients	Metachronous 94 patients	<i>p</i> value
Tumor diameter (mean) cm	0.3–23 (4.5)	0.9–18 (4.9)	0.4191
No. metastases (mean)	1–10 (2.2)	1–7 (1.6)	0.0133
Procedure (anatomical/partial)	48:22	81:13	0.0115
Invasive factor (yes/no)	17:44	40:45	0.0298

Tumor diameter and number of metastases were tested for significance with the *t* test, and surgical procedure and invasive factor with the chi-square test

cases, respectively. These differences between the groups were also insignificant (Fig. 2).

Discussion

There is much debate as to whether it is better to resect the liver simultaneously with the colon [2–6] or after an interval [7, 8] in cases of colorectal cancer with synchronous hepatic metastases. Few reports, however, mention the length of the interval or changes in hepatic metastatic foci during the interval in such cases of interval hepatic resection [7, 8]. In the present study, we analyzed the outcomes after hepatic resection for metastases of colorectal cancer at our hospital and investigated whether or not the policy of interval hepatic resection for synchronous liver metastases is reasonable.


Since 1983, the main procedure at our hospital for hepatic resection of colorectal cancer metastases has been

anatomical resection based on hemihepatectomy and lymph node dissection [1, 9]. Our basic policy has been to wait for an interval of 3 months after resection of the primary lesion and then conduct hepatic resection for the synchronous hepatic metastases. Of the 164 hepatic resection patients in the present study, 129 (78.7%) underwent anatomical resection. In the cases of synchronous liver metastases, 49 of 70 (70.0%) patients underwent hepatic resection after a mean interval of 131 days. In many cases in which synchronous colorectal and hepatic resection was performed, intraoperative palpation revealed a small lesion near the liver surface, and the colorectal surgeon performed a partial resection of the liver, which served as a biopsy.

In the survival analysis of these 164 patients, maximum diameter of hepatic metastasis was an independent prognostic factor [10]. The 3-, 5-, and 10-year cumulative survival rates were 71.9, 51.8, and 36.6%, respectively. There was recurrence in the remnant liver after hepatic resection in 44 (26.8%) patients, and both the postoperative survival rate and recurrence rate in the remnant liver, which indicates local control in the liver, were much better than in reports of other authors [10–14].

It is generally reported that the prognosis is poorer with synchronous hepatic metastases than with metachronous hepatic metastases [15–17]. In our patients, a comparison of background factors in the 70 patients with synchronous metastases and 94 patients with metachronous metastasis revealed no significant differences in tumor diameter, postoperative cumulative survival rate, or recurrence in the remnant liver. In this series of 164 patients, anatomical hepatic resection was performed in 129 (78.7%); among the 70 patients with synchronous metastases, interval hepatic resection was performed in 49 (70.0%). It is unclear how much the choice of procedure [11] and timing for the hepatic resection affected outcome, but among our patients, the

Fig. 2 Postoperative cumulative survival rate with synchronous and metachronous liver metastases



outcome was similarly favorable in cases of synchronous liver metastasis, in which the influence of the primary cancer remains strong, and in cases of metachronous metastasis.

Although there are very few reports on changes in liver metastatic foci during the wait for hepatic resection, or on optimal interval length, Lambert et al. [7] conducted a reevaluation after a mean interval of 6 months in 28 patients with resectable synchronous liver metastases, and reported that there were changes in the surgical indications for liver metastasis in 18 patients (65%) in whom new hepatic lesions or distant metastasis had appeared. Of the patients who underwent colon resection at our hospital between 1995 and 2004, 27 patients had no extrahepatic lesion remnants at the time of colorectal surgery and simultaneously resectable liver metastases. At an interval of 3 months after colorectal resection, there were changes in the planned hepatic resection procedure or surgical indications for liver metastasis in 15 patients (56%). An interval allows the surgeon to gain a more accurate understanding of the number and location of liver metastases from the primary tumor and is beneficial in determining surgical indications or selection of surgical procedure. This treatment policy is thought to contribute to improving the post-hepatectomy outcome and preventing recurrences in the remnant liver in patients with synchronous liver metastases.

From the above, we conclude that interval hepatic resection is a reasonable treatment strategy in cases of synchronous liver metastasis, and that it is beneficial not only in terms of selecting an appropriate procedure for hepatic resection but also in avoiding unnecessary hepatic resections. The liver metastases in our patients grew larger during the interval, and we currently consider an interval of about 3 months to be appropriate, although this will require further investigation in the future.

References

1. Yasui K, Hirai T, Kato T, Torii A, Uesaka K, Morimoto T, Kodera Y, Yamamura Y, Kito T, Hamajima N (1997) A new macroscopic classification predicts prognosis for patient with liver metastases from colorectal cancer. *Ann Surg* 226:582–586
2. Chua HK, Sondenaa K, Tsiotos GG, Larson DR, Wolff BG, Nagomey DM (2004) Concurrent vs staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. *Dis Colon Rectum* 47:1310–1316
3. Tanaka K, Shimada H, Matsuo K, Nagano Y, Endo I, Sekido H, Togo S (2004) Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. *Surgery* 136:650–659
4. Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D (2003) Simultaneous resection of colorectal primary tumour and synchronous liver metastases. *Br J Surg* 90:956–962
5. Martin R, Paty P, Fong Y, Grace A, Cohen A, DeMatteo R, Jamagin W, Blumgart L (2003) Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. *J Am Coll Surg* 197:233–241, discussion 241–242
6. Lyass S, Zamir G, Matot I, Goitein D, Eid A, Jurim O (2001) Combined colon and hepatic resection for synchronous colorectal liver metastases. *J Surg Oncol* 78:17–21
7. Lambert LA, Colacchio TA, Barth RJ (2000) Interval hepatic resection of colorectal metastases improves patient selection. *Arch Surg* 135:473–479, discussion 479–80
8. Bismuth H, Castaing D, Traynor O (1988) Surgery for synchronous hepatic metastases of colorectal cancer. *Scand J Gastroenterol (Suppl)* 149:144–149
9. Yasui K, Hirai T, Kato T, Morimoto T, Torii A, Uesaka K, Kodera Y, Yamamura Y, Kito T (1995) Major anatomical hepatic resection with regional lymph node dissection for liver metastases from colorectal cancer. *J Hepatobiliary Pancreat Surg* 2:103–107
10. Seifert JK, Bottger TC, Weigel TF, Gonner U, Junginger T (2000) Prognostic factors following liver resection for hepatic metastases from colorectal cancer. *Hepatogastroenterology* 47:239–246
11. Yasui K, Shimizu Y (2005) Surgical treatment for metastatic malignancies. Anatomical resection of liver metastasis: indications and outcomes. *Int J Clin Oncol* 10:86–96
12. Ambiru S, Miyazaki M, Isono T, Ito H, Nakagawa K, Shimizu H, Kusashio K, Furuya S, Nakajima N (1999) Hepatic resection for colorectal metastases: analysis of prognostic factors. *Dis Colon Rectum* 42:632–639
13. Nakajima Y, Nagao M, Ko S, Kanehiro H, Hisanaga M, Aomatsu Y, Ikeda N, Shibaji T, Ogawa S, Nakano H (2001) Clinical predictors of recurrence site after hepatectomy for metastatic colorectal cancer. *Hepatogastroenterology* 48:1680–1684
14. Belli G, D'Agostino A, Ciciliano F, Fantini C, Russolillo N, Belli A (2002) Liver resection for hepatic metastases: 15 years of experience. *J Hepatobiliary Pancreat Surg* 9:607–613
15. Beckurts KT, Holscher AH, Thorban S, Bollschweiler E, Siewert JR (1997) Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. *Br J Surg* 84:1081–1084
16. Hananel N, Garzon J, Gordon PH (1995) Hepatic resection for colorectal liver metastases. *Am Surg* 61:444–447
17. Scheele J, Stang R, Altendorf-Hofmann A, Paul M (1995) Resection of colorectal liver metastases. *World J Surg* 19:59–71

An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer

J Sakamoto^{*1}, C Hamada¹, S Yoshida¹, S Kodaira¹, M Yasutomi¹, T Kato¹, K Oba¹, H Nakazato¹, S Saji¹ and Y Ohashi¹

¹Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum; Secretariat, Department of Epidemiological & Clinical Research Information Management, Kyoto University, Graduate School of Medicine, Kyoto, Japan

Uracil–Tegafur (UFT), an oral fluorinated pyrimidine chemotherapeutic agent, has been used for adjuvant chemotherapy in curatively resected colorectal cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients with rectal cancer. The objective of this study was to perform a reappraisal of randomised clinical trials conducted in this field. We designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of UFT for curatively resected rectal cancer in terms of overall survival (OS), disease-free survival (DFS), and local relapse-free survival (LRFS). We analysed individual patient data of five adjuvant therapy randomised clinical trials for rectal cancer, which met the predetermined inclusion criteria. These five trials had a combined total of 2091 patients, UFT as adjuvant chemotherapy compared to surgery-alone, 5-year follow-up, intention-to-treat-based analytic strategy, and similar endpoints (OS and DFS). In a pooled analysis, UFT had significant advantage over surgery-alone in terms of both OS (hazard ratio, 0.82; 95% confidence interval (CI), 0.70–0.97; $P=0.02$) and DFS (hazard ratio, 0.73; 95%CI, 0.63–0.84; $P<0.0001$). This individual patient-based meta-analysis demonstrated that oral UFT significantly improves both OS and DFS in patients with curatively resected rectal cancer.

British Journal of Cancer (2007) 96, 1170–1177. doi:10.1038/sj.bjc.6603686 www.bjcancer.com

Published online 20 March 2007

© 2007 Cancer Research UK

Keywords: rectal cancer; UFT; adjuvant chemotherapy; randomised clinical trials; individual patient data meta-analysis

Colorectal cancer accounts for 10–15% of all cancers and is the second leading cause of cancer deaths in developed countries (Pisani *et al*, 1993). In Japan alone, nearly 56 000 new cases are diagnosed and this disease causes 36 000 deaths every year (Statistics and information department, Ministry of Health and Welfare, 1996). Surgical treatment is the primary management of colorectal cancers, with 75–80% of the patients being operable at the time of diagnosis (Boring *et al*, 1991; Vernaba *et al*, 1994). However, even if a curative resection is performed, those patients with regional lymph node involvement (Dukes' C, Stage III) have a 40–50% 5-year survival rate.

Recently, in the field of Stage III colon cancer treatment, adjuvant chemotherapy by 5-fluorouracil (5-FU)/levamisole was proved to be superior to surgery-alone therapy, and then various 5-FU/leucovorin (LV) regimens were confirmed to be effective

from the results of numerous large-scale randomised trials and from the pooled analysis of clinical trials (Wolmark *et al*, 1993; International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators, 1995; O'Connell *et al*, 1997). In 2004, results from the Multicenter International Study of Oxaliplatin/5-FU/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) trial demonstrated that combination chemotherapy with 5-FU/LV (de Gramont regimen) plus oxaliplatin was significantly superior to 5-FU/LV alone (André *et al*, 2004). With regard to adjuvant chemotherapy for colon cancer, therefore, solid evidence has been accumulated from relevant clinical trials, and steady evolution of the new treatment modalities has been achieved.

However, the situation is still uncertain focusing on adjuvant therapy for rectal cancer. Despite apparently curative surgery, rectal cancer recurs in more than 55% of the patients, including local recurrence rates of 25% (Vernaba *et al*, 1994). Despite the recommendation of the consensus conference by the National Institute of Health (NIH consensus conference, 1990) that concluded that adjuvant radiotherapy and chemotherapy should be given to all patients with locally advanced rectal cancer, recent findings by a large-scale randomised trial and meta-analysis have failed to prove significant benefit of radiotherapy for survival (Fisher *et al*, 1988; Vernaba *et al*, 1994). In this regard, the quest for an effective adjuvant treatment with a robust advantage on the

*Correspondence: Dr J Sakamoto, Young Leaders Program, Department of Social Life Science, Nagoya University Graduate School of Medicine, 65 Tsurumaicho, Showaku, Nagoya 466-8550, Japan; E-mail: sakamjun@med.nagoya-u.ac.jp

Previous presentation: The 41st annual meeting of American Society of Clinical Oncology, Orlando (*Proc Am Soc Clin Oncol* 2005; 23: 253s)

Received 1 December 2006; revised 19 February 2007; accepted 19 February 2007; published online 20 March 2007

outcome of resected rectal cancer remain an important task for gastrointestinal oncologists.

In Japan, mesorectal excision is standard surgical procedure. Radiotherapy is not routinely performed as adjuvant therapy.

In Japan, adjuvant therapy after resection of colorectal cancer was developed primarily using oral fluorinated pyrimidines (O-FPs). A meta-analysis of three old trials (Sakamoto *et al*, 1999) and a more sophisticated analysis of four recent pivotal randomised trials (Sakamoto *et al*, 2004) demonstrated a statistically significant benefit of O-FPs on the outcome of colorectal cancers over surgery alone. However, the survival benefit shown in that meta-analysis was more pronounced in colon cancers. The risk reduction in terms of rectal cancer was only 8% and the result of those previous meta-analyses that analysed various types of oral fluorinated pyrimidine clinical trials was not sufficient to show a significant effect on survival.

Uracil-tegafur (UFT) is one of the O-FPs. In colon cancer, the majority of recurrences occurred in the liver, whereas in rectal cancer many recurrences occurred in the lung and locally in addition to the liver. Treatment effect may thus differ between colon cancer and rectal cancer. As the previous meta-analysis, two trials of UFT in patients with rectal cancer have been reported. The present study focused on rectal cancer, which lacked a clear-cut survival benefit in our previous meta-analysis. Unlike oral fluoropyrimidines such as capecitabine and tegafur, the formulation of UFT includes a dihydropyrimidine dehydrogenase inhibitor (Diasio, 1999), designed to enhance the bioavailability of FU. This combination of uracil and tegafur was shown, in an animal tumour system, to increase the anti-tumour activity compared with tegafur alone (Ooi *et al*, 2001). UFT also produced an enhanced intratumoural concentration of fluorinated pyrimidine, 5–10 times greater than that achieved with Tegafur alone (Fukunaga *et al*, 1987). Preclinical studies established that the optimal molar ratio of uracil to Tegafur is 4:1, which resulted in the highest 5-FU tumour: blood and tumour: normal tissue partition coefficients (Kawaguchi *et al*, 1980). UFT has now been clinically tested for lung cancer (Kato *et al*, 2004), breast cancer (Noguchi *et al*, 2005), and for gastric cancer (Kinoshita *et al*, 2005) in an adjuvant setting in Japan. Recently, UFT has also been tested in Western countries, regarding its efficacy for both advanced and curatively resected colon cancer (Carmichael *et al*, 2002; Douillard *et al*, 2002; Lembersky *et al*, 2006).

Here, we present an individual patient data meta-analysis of five centrally randomised trials recently performed in Japan to compare rectal cancer patients treated with UFT, with the surgery-alone control group. This meta-analysis includes data from more than 2000 patients and therefore provides a more reliable assessment of the effect of UFT on the survival, disease-free survival (DFS), and local relapse-free survival (LRFS) of the patients with rectal cancer than is available from any of the individual studies.

PATIENTS AND METHODS

Selection of trials

Trials that randomly assigned patients to either long-term (12 months) administration of UFT or surgery-alone treatment after curative resection of rectal cancer were eligible for meta-analysis. The randomisation technique used in these trials was the centralised randomisation that precluded the possibility of prior knowledge of the treatment to be allocated.

Five relevant trials identified as Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) 7-1 (Kodaira *et al*, 1998), JFMC15-1, JFMC15-2 (Watanabe *et al*, 2004), Tokai Adjuvant Chemotherapy Study Group for Colorectal Cancer (TAC-CR) (Kato *et al*, 2002), and National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC) (Akasu *et al*, 2006) were included in the meta-analysis involving a total of 2091 patients. In trials JFMC7-1, JFMC15-1, and JFMC 15-2, patients who were randomly assigned to the experimental group received intravenous mitomycin C (6 mg m^{-2}) at 1 week and once monthly for 6 months. In the JFMC15-1 and 15-2 trials, patients who were randomly assigned to the experimental group additionally received an induction course of intravenous 5-FU ($250 \text{ mg daily}^{-1}$) during 7 postoperative days (Table 1).

Protocol and data collection for the meta-analysis

In December 2003, a protocol for the meta-analysis, describing the study rationale, statistical methods, and guidelines for publication, was distributed to the principal investigators of the five trials. Investigators were asked to provide individual data for every randomised patient, whether eligible or not, assessable or not, and

Table 1 Details of the randomized controlled trials included in the individual patient data meta-analysis

Category	JFMC7-1	JFMC15-1	JFMC15-2	TAC-CR	NSAS-CC	Total
Additional chemotherapy	Mitomycin C	Mitomycin C+FU IV	Mitomycin C+FU IV	None	None	—
Radiotherapy	None	None	None	None	None	—
UFT dose/day	400 mg	400 mg	400 mg	400 mg	600 mg ^a	—
Period	12 months	12 months	12 months	24 months	12 months	—
Dates of accrual	1986–1988	1989	1990	1991–1994	1996–2001	—
No. of patients	834	447	391	143	276	—
Duration of accrual, months	35	24	24	36	54	—
Sex, No. of patients (male–female ratio)						
Male	521 (62.4%)	260 (58.1%)	244 (62.4%)	93 (65.0%)	167 (60.5%)	1285 (61.4%)
Female	313 (37.6%)	187 (41.9%)	147 (37.6%)	50 (35.0%)	109 (39.5%)	806 (38.9%)
Duke's stage, No. of patients						
A	135	67	62	12	0	276
B	326	175	139	53	0	693
C	373	205	189	78	276	1121
Median age	57	60	59	62	58	58
Upper age limit, years	70	75	75	75	75	—

JFMC = Japanese Foundation for Multidisciplinary Treatment of Cancer; NSAS-CC = National Surgical Adjuvant Study of Colorectal Cancer; TAC-CR = Tokai Adjuvant Chemotherapy for Colorectal Cancer; UFT = Uracil-Tegafur. ^a400 mg m^{-2} day⁻¹ for 5 days every 7 days.

properly followed up or not. Items requested for every patient were as follows: patient identification, date of surgery, eligibility, allocated treatment by random assignment, age, sex, primary tumour site, Dukes' stage, induction chemotherapy, dates of recurrence, death, or last visit. Disease-free survival was calculated from the date of surgery to the date of recurrence, second primary cancer or death, whichever occurred first. Survival was calculated from the date of surgery to the date of death, regardless of the cause of death. Local relapse-free survival was calculated from the date of surgery to the date of local recurrence. Data from patients with only distant recurrence and those who were died without recurrence were censored. Patients enrolled in these trials had been followed up for 5–7 years. Toxicity data were not collected, because detailed analysis of side effects can be found in the published reports of the individual trials (Kodaira *et al*, 1998; Kato *et al*, 2002; Watanabe *et al*, 2004; Akasu *et al*, 2006).

All investigators and the Clinical Trial Committee of all the trials agreed to join in the meta-analysis. Individual patient data were received by the independent secretariat by February 2004 and October 2006.

Pretreatment patient characteristics

All 2091 patients had curatively resected rectal cancer without evidence of distant metastasis by diagnostic imaging criteria or by macroscopic examination of the abdominal organs during surgery. Patients with severe postoperative complications were excluded from all trials, as were patients with any previous chemotherapy or radiotherapy or with a synchronous or metachronous second cancer. Median patient age was 61 years at the time of random assignment. The male/female ratio was approximately 3:2. Performance status was less than 2 on the Japan Clinical Oncology Group scale for all patients.

Statistical analysis

The method used for the meta-analysis and the format for the presentation of the results have been described in detail elsewhere (Advanced Colorectal Cancer Meta-Analysis Project, 1992). All analyses were based on individual patient data. Treatment effects on DFS, LRFS, and survival were first estimated within each trial and then combined using classical meta-analytic methods (Colorectal Cancer Collaborative Group, 2001). Treatment effects were displayed as hazard ratios. These ratios were estimated by univariate Cox's proportional model as relative risks of having an event in the UFT group as compared with having the same

event in the surgery-alone control group. A ratio less than unity indicates benefit from UFT, and this benefit is statistically significant when the 95% confidence interval (CI) of the ratio does not include unity. The overall effect of treatment was assessed through a χ^2 d.f. and the heterogeneity between five trials through a χ^2 d.f. (Colorectal Cancer Collaborative Group, 2001). Additional analyses were carried out to determine which of the following prognostic features, if any, were predictive of the treatment effect: Dukes' stage (A vs B vs C), sex (male vs female), and age (three groups of increasing age). Tests for interaction were applied to detect departures from the homogeneity of treatment effects. Multivariate analyses were performed with the use of the Cox proportional hazards regression model for DFS, LRFS, and survival to assess the robustness of the observed effects to adjustments for important covariates and the magnitude of interaction between treatment effect and covariate (Advanced Colorectal Cancer Meta-Analysis Project, 1992). All *P*-values resulted from use of two-sided statistical tests. The significance level was set at 5% for all tests.

RESULTS

Survival

Survival hazard ratios for all the trials are presented in Figure 1. The overall hazard ratio was 0.82 (95% CI, 0.70–0.97; *P*=0.02) with no significant heterogeneity between the treatment effects in different trials (χ^2 for heterogeneity=4.31; *P*=0.37). UFT showed significant effect on survival of curatively resected rectal cancers with a 5-year survival benefit of approximately 5%.

Figure 2 shows the breakdown of the survival hazard ratio stratified by various patient characteristics. There was a slight trend toward larger treatment benefits in earlier Dukes' stages (Hazard ratio; Dukes' A=0.60, Dukes' B=0.79, Dukes' C=0.86) but heterogeneity tests did not show any significant difference (χ^2 =1.41; *P*=0.495). There was no statistically significant difference in sex (χ^2 for interaction=1.62; *P*=0.204) or age (χ^2 for interaction=0.22; *P*=0.898).

Figure 3 shows survival curves by treatment and disease stage. These curves confirm the hazard ratio analysis shown in Figure 2 and point to favourable effects of UFT in all Dukes' stages.

Disease-free survival

Disease-free survival hazard ratios are presented in Figure 4 for all the trials. These figure show a somewhat larger effect of treatment on DFS than on survival, with an overall DFS ratio of 0.73 (95%CI,




Figure 1 Survival hazard ratios by individual trial (Abbreviations: O/N=observed number of events/number of patients; O-E=Observed minus Expected number of events; V=variance of (O-E); Hazard Redn=hazard reduction; SE=standard error of hazard reduction).





Figure 2 Survival hazard ratios by patient and treatment characteristics (Abbreviations as in Figure 1).



	No. at risk							
	Treatment	Control	148	128	125	145	139	137
Dukes A	Treatment	Control	148	128	125	145	139	137
Dukes B	Treatment	Control	377	316	343	328	316	304
Dukes C	Treatment	Control	589	532	494	438	388	357
			532	507	442	374	339	299

Figure 3 Survival curves by tumour stage and by treatment.

0.63-0.84; $P < 0.0001$) with a 5-year DFS benefit of 9.7%, but demonstrating some heterogeneity among the treatment effects in different trials (χ^2 for heterogeneity = 7.85; $P = 0.097$). Additionally, random effect model assuming the variation between trials was applied. The results of the random effect model still revealed highly significant differences owing to the relatively high effect in TAC-CR and NSAS-CC trials.

Figure 5 lists the DFS hazard ratios by various patient and treatment characteristics.

Figure 6 shows DFS curves by treatment and disease stage. These curves again point to benefits of UFT in Dukes' A, B and C stages. Roughly identical effect extended across all Dukes' stages: the DFS benefits at 5 years in terms of risk reduction were 0.42, 0.33, 0.23.

Local relapse free survival

The overall hazard ratio was 0.68 (95%CI, 0.53-0.87; $P = 0.0026$), and demonstrating some heterogeneity among the treatment




Figure 4 Disease-free survival hazard ratios by individual trial (Abbreviations as in Figure 1).




Figure 5 Disease-free survival hazard ratios by patient and treatment characteristics (Abbreviations as in Figure 1).


effects in different trials (χ^2 for heterogeneity = 8.82; $P = 0.0658$). UFT also showed significant effect on LRFS of curatively resected rectal cancers.

DISCUSSION

Extensive preclinical and clinical research led to the optimisation of 5-FU administration, with 5-FU bolus in combination with LV as standard therapy both in metastatic disease (Advanced Colorectal Cancer Meta-Analysis Project, 1992) and after curative resection of Stage III (Dukes' C) colon cancer (International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators, 1995; O'Connell et al, 1997; Wolmark et al, 1999).

However, the toxicity of bolus 5-FU/LV regimen, especially the risk of haematologic toxicity and mucositis, could not have been negligible.

Continuous-infusion 5-FU modulated by LV, utilised mostly in European countries, showed somewhat better efficacy and definitely better tolerance than bolus 5-FU in advanced diseases (de Gramont et al, 1997; Meta-Analysis Group In Cancer, 1998a,b; Schmoll et al, 2000). In the adjuvant setting, one of the continuous regimens (LV5-FU2) was shown to have low toxicity than the bolus regimen, but no difference was shown in terms of survival (André et al, 2003). Recently, combination of continuous 5-FU/LV and oxaliplatin (FOLFOX 4) was demonstrated to have significant effect on DFS, and is now considered as the standard adjuvant regimen for colon cancer in the Western world.



	No. at risk						
Dukes A	Treatment	148	147	143	140	134	132
	Control	128	124	119	115	111	108
Dukes B	Treatment	377	347	315	303	291	282
	Control	316	280	250	237	217	206
Dukes C	Treatment	589	487	403	354	320	298
	Control	532	396	323	277	251	227

Figure 6 Disease-free survival curves by tumour stage and by treatment.

The recent development of O-FPs has therefore opened new perspectives. Oral fluorinated pyrimidines may mimic continuous regimens without its technical inconvenience and deterring patients' quality of life. In patients with advanced colorectal cancer, the efficacy of UFT (typical and most prescribed O-FP) plus oral LV (Carmichael *et al*, 2002; Douillard *et al*, 2002) or of capecitabine alone (Hoff *et al*, 2001; Van Cutsem *et al*, 2001) seems comparable in terms of the efficacy with significantly less significant severe haematologic toxicities and/or stomatitis. The risk of severe hand-foot syndrome is lower in UFT than with capecitabine, but the risk of severe diarrhoea and other gastrointestinal symptoms is higher in UFT and in UFT/oral LV treatment for Western patients.

In Japan, UFT have been administered for many years especially for patients with curatively resected colorectal cancers. For some unknown reason, severe gastrointestinal toxicities are much less frequent in Japanese patients, and patients usually prefer oral chemotherapy especially in an adjuvant setting (Borner *et al*, 2002).

Furthermore, with regard to rectal cancer, it is a difficult objective for a clinical trial to accrue enough patients, compared to colon cancer, and despite the fact that several attempts of determining a standard adjuvant treatment for rectal cancer, almost no clinical trial has succeeded in showing a relevant survival benefit of adjuvant treatment, except one with preoperative radiotherapy (Swedish Rectal Cancer Trial, 1997).

In this context, several Japanese groups conducted randomised clinical trials comparing UFT with surgery alone for curatively resected rectal cancers. Five such trials were identified after a meticulous search, and are included in the present meta-analysis. This meta-analysis was restricted to trials that had been randomised centrally and from which no patient had been excluded for any reason. It represents the largest series of properly randomly assigned patients receiving the single oral adjuvant O-FP agent, that is, UFT, for rectal cancer comparing with patients receiving no therapy after curative tumour resection.

This meta-analysis found a statistically significant benefit of UFT with regard to overall survival (OS) (hazard ratio = 0.82; $P = 0.02$) as well as DFS (hazard ratio = 0.73; $P < 0.0001$), and LRFS (hazard ratio = 0.68; $P = 0.0026$). As can be seen by comparing the data in Figures 1 and 4, the data from the NSAS-CC and TAC-CR

study show benefits that are, apparently, larger than the others. As shown in Table 1, the dosage and duration of treatment with UFT in the NSAS-CC and TAC-CR trials differed from those in the other three trials; the dose intensity of UFT was higher in the former two trials. Several studies have reported that a high-dose intensity of UFT improves survival in patients given postoperative adjuvant chemotherapy for gastric cancer (Sugimachi *et al*, 1997; Danno *et al*, 2001). The higher dose intensity of UFT in the NSAS-CC and TAC-CR trials may have influenced the outcomes.

Most of the Japanese rectal cancer patients did not receive pre- or postoperative radiotherapy in any of the trials. Although radiotherapy has been considered one of the standard adjuvant treatments in the Western countries, significant survival benefit has not been shown with reproducibility (Wolmark *et al*, 2000; Colorectal Cancer Collaborative Group, 2001). The ostensible advantage of adjuvant radiotherapy is to decrease local recurrence of rectal cancers. As compared with postoperative chemoradiotherapy, preoperative chemoradiotherapy does not improve OS, but inhibits local recurrence and reduces toxicity (Sauer *et al*, 2004). In our study, however, LRFS was also significantly better in the UFT group compared to surgery alone group. As far as our results are concerned, UFT might also be useful in preventing local recurrence in Japanese patients who usually do not receive radiotherapy in an adjuvant setting.

Also, there is still a debate whether adjuvant chemotherapy for early stage rectal cancer is feasible (Buyse and Piedbois, 2001). In terms of numbers needed to treat, these benefits imply that approximately 20 patients need to be treated for one more patient to survive 5 years, and approximately 10 to be treated for one fewer patient to suffer a cancer recurrence within 5 years, regardless of disease stage. Our results show that the therapy is beneficial in Stage II patients not only Stage III patients with nodal involvement (Mamounas *et al*, 1999; Gray *et al*, 2004). As for early stage disease, further investigations are needed to assess potential benefits of treatment because events were infrequent and hazard ratios were small.

Regardless of the disease stage and patient background characteristics, there is a need for further trials involving UFT and new agents that are effective in advanced disease, such as irinotecan, oxaliplatin, and monoclonal antibodies.

ACKNOWLEDGEMENTS

This work is supported in part, by non-profit organization Epidemiological & Clinical Research Information Network (ECRIN), Kyoto University EBM Collaborating Center, and grant-in aid from Japanese Society for Cancer of the Colon and Rectum, from

Japanese Society for Strategies of Cancer Therapy, and from Osaka Cancer Foundation. The authors are indebted to Professor J Patrick Barron of the International Medical Communications Center of Tokyo Medical University for his review of this article.

REFERENCES

- Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. *J Clin Oncol* 10: 896-903
- Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S, NSAS-CC Group (2006) Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. *Jpn J Clin Oncol* 36: 237-244
- André T, Boni C, Mounedji-Boudiaf L, Navarro M, Taberero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med* 350: 2343-2351
- André T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A (2003) Bi-monthly regimen of 5-fluorouracil and leucovorin (LV5FU2) as adjuvant therapy in stage II and III colon cancer: 4-year results of a randomised trial. *J Clin Oncol* 21: 2896-2903
- Boring CC, Squires TS, Tong T (1991) Cancer statistics. *CA Cancer J Clin* 41: 19-51
- Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT vs intravenous fluorouracil leucovorin: a randomised crossover trial in advanced colorectal cancer. *Eur J Cancer* 38: 349-358
- Buyse M, Piedbois P (2001) Should Dukes' B patients receive adjuvant chemotherapy? A statistical perspective. *Seminars Oncol* 28(Suppl 1): 20-24
- Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C (2002) Randomized comparative study of tegafur/uracil and oral leucovorin vs parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 20: 3617-3627
- Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. *Lancet* 358: 1291-1304
- Danno M, Shiroto H, Kunii Y, Ishibiki K, Yamamura Y, Sakamoto Y, Tamura Y, Kunitomo K, Kumashiro R (2001) Study on the intensity of MMC and UFT in postoperative adjuvant chemotherapy for gastric cancer-study report of JFMTCC Study No. 10. *Jpn J Cancer Chemother* 28: 195-203
- de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. *J Clin Oncol* 15: 808-815
- Diasio RB (1999) Clinical implications of dihydropyrimidine dehydrogenase inhibition. *Oncology* 13: 17-21
- Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin vs fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 20: 3605-3616
- Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, Fisher ER, Caplan R, Jones J, Lerner H, Gordon P, Feldman M, Cruz A, Legault-Poisson S, Wexler M, Lawrence W, Robidoux A, Other NSABP Investigators (1988) Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. *J Natl Cancer Inst* 80: 21-29
- Fukunaga H, Katsumi M, Aoki Y, Oka S, Konishi R, Yukawa H, Kawaguchi T, Tamaki Y, Takifuji K (1987) 5-FU concentration in tumor tissue and the antitumor effect in patients with gastric cancer after oral administration of UFT. *Jpn J Cancer Chemother* 14: 2735-2739 (in Japanese)
- Gray RG, Barnwell J, Hills R, McConkey C, Williams N, Kerr D, for the QUASAR Collaborative Group (2004) QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. *Proc Am Soc Clin Oncol* 23: 246 (abstr 3501)
- Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine vs intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. *J Clin Oncol* 19: 2282-2292
- International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. *Lancet* 345: 939-944
- Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M, Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. *N Engl J Med* 350: 1713-1721
- Kato T, Ohashi Y, Nakazato H, Koike S, Saji S, Suzuki H, Takagi H, Nimura Y, Hasumi A, Baba S, Manabe T, Maruta M, Miura K, Yamaguchi A (2002) Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. *Langenbecks Arch Surg* 386: 575-581
- Kawaguchi Y, Nagayama S, Masuda H, Yasuda A (1980) Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats. *Gann* 71: 889-899
- Kinoshita T, Nakajima T, Ohashi Y, National Surgical Adjuvant Study Group of Gastric Cancer (2005) Survival benefit of adjuvant chemotherapy with Uracil-tegafur (UFT) for serosa negative advanced gastric cancer (AGC): Results of a randomized trial by National Surgical Adjuvant Study of Gastric Cancer. *Proc Am Soc Clin Oncol* 23S: 313s (abstr 4021)
- Kodaira S, Kikuchi K, Yasutomi M, Takahashi T, Hojo K, Kato T, Tomimaga T, Kunii Y (1998) Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer. Results from the Cooperative Project No. 7 Group of the Japanese Foundation for Multidisciplinary Treatment of Cancer. *Int J Clin Oncol* 3: 357-364
- Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. *J Clin Oncol* 24: 2059-2064
- Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). *J Clin Oncol* 17: 1349-1355
- Meta-Analysis Group In Cancer (1998a) Toxicity of 5-fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. *J Clin Oncol* 16: 1-6
- Meta-Analysis Group In Cancer (1998b) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. *J Clin Oncol* 16: 301-308
- NIH Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. *JAMA* 264: 1444-1450
- Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, Akazawa K, Abe O (2005) Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. *J Clin Oncol* 23: 2172-2184

- O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. *J Clin Oncol* 15: 246–250
- Ooi A, Ohkubo T, Higashigawa M, Kawasaki H, Kakito H, Kagawa Y, Kojima M, Sakurai M (2001) Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine. *Biol Pharm Bull* 24: 1329–1331
- Pisani P, Parkin DM, Ferlay J (1993) Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. *Int J Cancer* 55: 891–903
- Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y (1999) Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: Individual patient data meta-analysis of randomized trials. *Jpn J Clin Oncol* 29: 78–86
- Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P (2004) Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum; Meta-Analysis Group in Cancer. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. *J Clin Oncol* 22: 484–492
- Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidgerger H, Raab R, German Rectal Cancer Study Group (2004) Preoperative vs postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 351: 1731–1740
- Schmoll HJ, Köhne CH, Lorenz M, Schöffski P, Voigtmann R, Bokemeyer C, Lutz MP, Kleeberg U, Ridwelski K, Souchon R, El-Sarafi M, Weiss U, Couvreur ML, Baron B, Wils JA (2000) Weekly 24 h infusion of high-dose (HD) 5-fluorouracil (5-FU24 h) with or without folinic acid (FA) vs bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): a randomized phase III study of the EORTC GITCCG and the AIO. *Proc Am Soc Clin Oncol* 19: 241a (abstr 935)
- Statistics and information department, Ministry of Health and Welfare (1996) Deaths and death rates by sex and causes of death: Japan 1995 and 1994. In: *Vital Statistics of Japan*, vol 1, p 465. Health and Welfare Statistics Association: Tokyo
- Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita M (1997) Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. *Cancer Chemother Pharmacol* 40: 233–238
- Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. *N Engl J Med* 336: 980–987
- Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P (2001) Oral capecitabine compared with with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: results of a large phase III study. *J Clin Oncol* 19: 4097–4106
- Vernaba AM, Longo WE, Virgo KS, Coplin MA, Wade TP, Johnson FE (1994) Current follow up statistics after resection of colorectal cancer. *Dis Colon Rectum* 37: 573–583
- Watanabe M, Nishida O, Kunii Y, Kodaira S, Takahashi T, Tominaga T, Hojo K, Kato T, Niimoto M, Kunitomo K, Isomoto H, Ohashi Y, Yasutomi M (2004) Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur. *Int J Clin Oncol* 9: 98–106
- Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, L Ore L, Petrelli NJ (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. *J Clin Oncol* 11: 1879–1887
- Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from national surgical adjuvant breast and bowel project C-04. *J Clin Oncol* 17: 3553–3559
- Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, Wexler M, Prager D, Cruz Jr AB, Gordon PH, Petrelli NJ, Deutsch M, Mamounas E, Wickerham DL, Fisher ER, Rockette H, Fisher B (2000) Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. *J Natl Cancer Inst* 92: 388–396

大腸癌肝転移に対する治療

大腸癌肝転移に対する手術療法

加藤 知行

愛知県がんセンター中央病院長

はじめに

大腸癌肝転移に対する治療の第1選択が肝切除であることに異論はない。100例以上の症例を集積した報告で肝切除例の予後を見ると(表1)、症例集積期間はさまざまではあるが、報告年度が新しいものほど5年生存率は向上している。肝切除後の再発は残肝再発が40%、次いで肺転移が20%に見られる¹⁾。

肝切除後の予後不良因子(表2)として異論がないのは、剥離断端の癌露出、肝所属リンパ節転移陽性、衛星病変など肝転移進展因子陽性、肝外転移であり、さらに予後に大きく影響を与える因子として、肝転移個数、肝切除断端距離(tw)、肝転移切除後のCEA値とCA19-9値などが挙げられる。

本稿では、大腸癌肝転移に対する手術療法について現在の討議点を中心に解説する。

肝切除の適応

肝切除のstandard criteriaを表3に示す。肝転移症例のうち、切除可能なものは25~50%である³⁾。

現在では肝以外の臓器に転移があっても、それが完全切除できれば肝転移、他臓器転移ともに切除することが多い。また、肝転移巣切除後の残肝再発についても初回手術と同じ基準で切除の対象となり、初回手術と同様の予後が期待できる。

肝切除に関する討議点

1) 切除時期

同時性肝転移に対しては、原発巣と同時に切除するものと、まず原発巣を切除して、その後3カ月ほど待って肝転移巣を切除するものがある。

同時切除を行う理由は、①経過観察をしても予後に変わりはなく、②術前・術中の画像診断で小病巣も把握できるから

遅らせる必要はない、③3カ月遅らせることで肝切除の時期を逃す、あるいは肝転移巣からの2次転移の危険性があるなどである。

異時切除を行う理由は、①肝転移状況や肝外転移の精査、②肝切除を同時に行うことによる死亡率や合併症率が高い、③同時に行くと微小転移を診断できないことがあるので、隠れた転移巣が明らかになるまで待って肝切除を行う、というものである。

原発巣切除は肝転移巣切除に先行して、あるいは同時に行われるのが一般的であるが、Menthaら⁴⁾は、多発肝転移や大きな肝転移では原発巣手術後に肝転移巣が進展する危険性があるため、大腸癌の狭窄症状がない症例ではまずneoadjuvant chemotherapyを行い、6コース(肝転移奏効例では3コース)後にまず肝切除を行い、その3~8週後に原発巣の手術を行う方法を提唱している。

2) 肝転移個数と大きさから見た適応

一般に、単発例は多発例よりも予後が良く、転移個数の多いものはそれ以下のものと比べて予後は不良である。その理由は、転移個数が多いものでは切除断端距離を十分に取れないことが予後不良の理由ではないかと推測されている。腫瘍径が小さいもの、特に3cm以下のものはそれ以上のものと比べて予後は良い。一方、切除断端の距離(tw)を十分に取って切除すれば、転移個数や大きさは予後に関係しないとする報告も少なくない。

3) 切除断端距離(tw)

切除断端に癌が露出しているものの予後は不良である。さらに、切除断端が陰

表1 肝転移切除例の予後(報告例)

報告者	発表年	paper	症例数	集積期間	5年生存率(%)
Wilson SM	1976	Arch Surg 111	60		26
Adson MA	1984	Arch Surg 119	141		25
Hughes KS	1986	Surgery 100	607		33
Scheele J	1991	Surgery 110	266	1960-1988	31
Doci R	1991	Br J Surg 78	100	1980-1989	30
Gayowsky TJ	1994	Surgery 116	204	1981-1991	32
Noldinger B	1996	Cancer 77	1568	1968-1990	28
Jamison RL	1997	Arch Surg 132	280		27
Fong Y	1997	J Clin Oncol 15	456	1985-1991	38
Beckurts KTE	1997	Br J Surg 84	126	1987-1994	14
Elias D	1998	Eur J Surg Oncol 24	269	1984-1996	34
Iwatsuki S	1999	J Am Coll Surg 189	305		32
Ambiru S	1999	Dis Colon Rectum 42	168	1984-1997	26
Fong Y	1999	Ann Surg 230	1001	1985-1998	37
Minagawa M	2000	Ann Surg 231	235	1980-1997	38
Sugihara K	2000	Ann Chirur Gynec 89	330	1985-1997	44
Belli G	2002	J Hepatobill Pancreat Surg 9	181	1986-2000	40
Choti MA	2002	Ann Surg 235	226	1984-1999	40
Kato T	2003	Dis Colon Rectum 46	585	1992-1996	39
Adam R	2006	Proc ASCO #3521	2122	1974-2004	42

性でもtwが10mm以下の症例の予後は不良とされ、twを10mm以上取ることは肝切除時の主要な目標であった。一方、肝転移巣周辺の衛星病変の頻度は少なく、存在する範囲も転移巣からわずかの距離であり、肝切除前の転移存在診断が確実に行えるようになった現在では、断端(一)であれば切除距離には関係しないとする報告も多い。

4) 肝切除術式と肝所属リンパ節郭清

肝切除術式は局所切除、区域切除、葉切除、拡大葉切除(3区域切除)などが

行われ、大きく分けて、解剖学的肝系統切除と非解剖学的肝局所切除とに分類される。基本術式が解剖学的系統切除か非解剖学的部分切除かについては解決していない。

肝門部リンパ節転移は13~25%^{1,6)}にみられ、他部位へ転移しているsignalであるとされる。その予後は不良で、現在では肝門部リンパ節転移例は手術適応外とすることが世界的なコンセンサスである。

転移陽性リンパ節郭清例の5年生存率は0~42%⁶⁾で、5年生存率は低いものの肝

門部リンパ節郭清を行うことで生存期間が延長するという報告も多い。

予防的肝門部リンパ節郭清の評価は定まっていない。

切除不能肝転移例の対応

1) Neoadjuvant chemotherapy

Bismuthら⁶⁾は、切除不能例に5-FU/ folinic acid/oxaliplatin併用療法を先行し、腫瘍の縮小を待って局所的に根治切除が可能となった時点で肝切除を行った。53例中46例に肉眼的根治切除が行え、非治癒切除となった7例には、門脈塞栓術により残肝の増大を図り化学療法を続けて第2期切除を行った結果、5年生存率は40%、残肝再発66%、肝外再発47%と報告した。これ以後、切除不能例に対してneoadjuvant chemotherapyを行い、腫瘍の縮小が得られたものに切除を行う報告は多い。

2) 残肝量が少ない症例の対応

肝切除後の残肝容積が25%以下の場合90%が肝機能障害を起し、慢性の肝疾患がある患者や大量の化学療法を受けた患者では40%以上の残肝量が要るとされる。そこで非腫瘍部の肝を40%以上温存できない場合には術前に片側の門脈塞栓術あるいは門脈結紮を行い予定残肝容積増大を促す適応となる。

3) Two stage operation

Bismuthら⁶⁾およびAdamら⁷⁾は、多発肝転移で切除不能と思われる症例に対して、術前化学療法、門脈塞栓術を行ってもone stageで完全切除ができない場合はtwo stage手術を提唱している。第I期手術では、できるだけ多くの転移巣を切除して、残肝の肥大を待つ間全身化学

表2 肝転移切除例の予後不良因子²⁾

原発巣因子	肝転移巣因子
<ul style="list-style-type: none"> 腹膜転移: P+ 組織型: por / muc 壁深達度: si / ai リンパ節転移: > n3 リンパ節転移個数: > 4 ew: + 	<ul style="list-style-type: none"> H因子: H3 (大腸癌取扱い規約 6版) 転移個数: > 4 最大径: > 3cm 転移巣の遺残: あり tw ≤ 10mm 肝門部リンパ節転移: あり 肝転移進展因子陽性 門脈腫瘍塞栓、肝静脈腫瘍塞栓 胆管内腫瘍進展、隣接臓器浸潤 肝内微小転移、神経周囲浸潤 転移巣周囲皮膜形成なし Liver cell entrapment
肝転移治療前因子	その他
<ul style="list-style-type: none"> 転移時期: 同時 CEA・CA19-9 > 正常値 CEA doubling time 短い 	<ul style="list-style-type: none"> 他臓器転移: あり 肝切除後CEA・CA19-9 > 正常値

表3 肝切除のstandard criteria

<ul style="list-style-type: none"> 外科切除のriskが低い 原発巣がコントロールされている 適度な残肝量を残して転移巣が完全に切除できる 肝転移以外の転移巣がない 肝所属リンパ節転移がない
<ul style="list-style-type: none"> 肝転移個数が4個以下 切除断端のclear margin (tw) が10mm以上切除できる

療法で遺残腫瘍の増大と転移を防ぎ、肝肥大が起きて完全切除ができるようになれば第Ⅱ期手術を行うものである。報告では、第Ⅰ期手術では無かった術死が15%にあり合併症もⅡ期手術では多い。

4) 肝切除と凝固療法の併用

多発転移に対しては、ラジオ波凝固療法(RFA)と肝切除の併用が行われており、Curleyら⁸⁾の報告では肝切除の5年生存率65%、肝切除とRFAの併用36%、RFA単独22%であった。注意しなくてはならないのは、併用療法が肝切除単独やRFA単独治療と比べて術後の合併症が20%前後と高く、手術死亡もあることである。

Eliasら⁹⁾は、肝切除量が大きくなって残肝機能を維持できない21症例に対して、切除線上の転移巣をRFAで焼灼して壊死させ、その壊死部上で肝を切除し、

小転移巣はRFAで焼灼した結果、術死の1例を除いて切除線上の局所再発はなかったと報告している。

また、肝切除の補助療法として断端陽性例、あるいはtwが10mm未満の症例に同部の凍結療法、マイクロ波凝固壊死療法やラジオ波熱凝固療法などの凝固療法を行う報告もある。

おわりに

大腸癌肝転移に対して治癒が期待できる治療は肝転移巣切除しかない。肝転移切除不能例に対しては、抗癌剤の肝動注療法あるいは全身化学療法を行うのが今までの治療戦略だった。現在の検討課題は、いかにして切除例の治癒度を高め、いかにして切除不能例を治癒切除が可能状況にするかという点である

文献

- 1) Kato T, Yasui K, Hirai T, et al: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: Analysis of prognostic factors for 763 cases recorded at 18 institutions. *Dis Colon Rectum* 46(suppl): S22-S31, 2003.
- 2) 加藤知行, 安井健三, 平井孝, 他: 大腸癌の肝転移に関する外科治療. 大腸疾患NOW2004, 初版, 武藤徹一郎監修, 日本メディカルセンター, 東京, 89-104, 2004.
- 3) 山本順司, 杉原健一: 肝転移: 外科治療. 臨床腫瘍学second ed. 第1版, 日本臨床腫瘍研究会編, 癌と化学療法社, 東京, 1645-1657, 1999.
- 4) Mentha G, Majno PE, Andres A, et al: Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. *Br J Surg* 93: 872-878, 2006.
- 5) Elias DM, Ouellet J: Incidence, distribution, and significance of hilar lymph node metastases in hepatic colorectal metastases. *Surg Oncol Clin N Am* 12: 221-229, 2003.
- 6) Bismuth H, Adam R, Lévi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. *Ann Surg* 224: 509-520, 1996.
- 7) Adam R, Lucidi V, Bismuth H: Hepatic colorectal metastases; methods of improving resectability. *Surg Clin North Am* 84: 659-671, 2004.
- 8) Curley SA: Outcomes after surgical treatment of colorectal cancer liver metastases. *Semin Oncol* 32(suppl): S109-S111, 2005.
- 9) Elias D, Manganas D, Benizri E, et al: Transmetastasis hepatectomy: Results of a 21-case study. *Eur J Surg Oncol* 32: 213-217, 2006.

腹会陰式直腸切断術

—出血させない手術操作に重点をおいて—

加藤 知行* 平井 孝* 金光 幸秀* 小森 康司*

はじめに

直腸癌に対する直腸切断術は、器械吻合の発達などで低位前方切除・超低位前方切除が普及してきたためその適応は減少しているものの、直腸癌に対する代表的な術式である。

直腸切断術には腹会陰式と腹仙骨式（仙骨腹式）とがあるが、腹会陰式は腹仙骨式（仙骨腹式）と比べて体位変換が容易で呼吸循環器系の麻酔管理が安全であり、また十分な手術操作ができるので一般的である。本稿では腹会陰式直腸切断術式について、とくに出血させない手術操作に重点をおいて解説する。

I. 適 応

下部直腸進行癌に対する治癒切除術式として、直腸切断術あるいは直腸低位前方切除術のいずれの術式を選択しても、直腸間膜内リンパ節と側方リンパ節郭清は同じように行える。直腸切断術と直腸低位前方切除術との郭清範囲の違いは肛門管よりも下方向の郭清、すなわち大腸癌取扱い規約第6版までは下直腸リンパ節と称していたものも含めて、坐骨直腸窩に存在する直腸壁在リンパ節（No.251）の郭清ができる

* Tomoyuki KATO et al. 愛知県がんセンター中央病院消化器外科（☎ 464-8681 愛知県名古屋市千種区鹿子殿 1-1）

key words : 腹会陰式直腸切断術, 直腸癌

か否かの違いである。しかし、現在では下部直腸癌において坐骨直腸窩にリンパ節転移およびリンパ節そのものもその存在を認めることは非常にまれである、あるいは認めないとするのが通説となっており、少なくとも坐骨直腸窩のリンパ節郭清を主目的として直腸切断術を選択することはなくなった。したがって、直腸切断術と低位前方切除術での根治術上の違いは肛門側への癌壁内進展に対する腸管切除量の違いといつてよい。

近年は肛門管へ癌が進展する症例に対しても内肛門括約筋切除や外肛門括約筋切除を行って吻合しようとする術式が試みられているが、いまだ臨床試験段階の術式であり、我々は原則として腹会陰式直腸切断術の適応を、腫瘍下縁から十分なAWを切除したうえで低位前方切除で結腸直腸吻合に必要な縫い代分約1cmが確保できない直腸癌症例としている。下部直腸癌における肛門側への癌の壁内進展は2cmまでがほとんどであり、分化型腺癌であればAWの切除量は3cmでよいと考えている。壁深度が固有筋層（mp）や粘膜下層（sm）などであれば、肛門機能を温存するためにAWは2cmでもよしとしている。低分化腺癌では遠く離れた肛門側壁内進展があるので4cm以上切除する。

II. 術前準備

患者には外来で病名・術式と人工肛門ができることを説明し、入院したらストーマサイト

マーキングを行う。

III. 手術手技

出血させない手術は十分に術野を展開し、剝離を進める層と切離する組織を直視下に視認して操作を進めることにつぎる。

1. 体位

股関節を軽く屈曲した載石位、骨盤高位とする。執刀者は患者の左側に立つ。

2. 開腹

恥骨結合上縁より臍の右側を通して臍より約8 cm 頭側までの腹部正中切開（図1）。開創器を掛けて小腸を intestinal bag に納めて腹腔外へ出す。

留意点：①横行結腸が腹腔外へ垂直に持ち上げられ、下腸間膜動脈根部の処理が無理なく行えるように十分に大きく開腹して術野を得ることが肝要である。②皮膚切開が臍の右側を通るのは、人工肛門を左側腹部に造設するので装着した人工肛門装具の面板が手術創にかかる部分を少なくするためである。③開創器は鉤が2葉のものだと開腹創は紡錘状になって頭側（下腸




図1 ストーマサイトマーキングと皮膚切開

間膜根部）と尾側（骨盤内）の視野が十分に得られない。鉤が4葉のものを使い、頭側から尾側まで十分に開創するようにし、必要に応じて開創器を動かして操作する術野を展開できるものがよい。

3. S状結腸の授動と下腸間膜動脈根部の切離

S状結腸と左壁側腹膜の癒着を剝離し、ついでS状結腸間膜を腎筋膜前葉を背側へ落として剝離・授動する。頭側は下腸間膜動脈根部の高さまで、尾側は左総腸骨動脈あたりまで、内側は大動脈の右側まで露出しておく（図2a）。

留意点：腎筋膜前葉を確認して腸間膜から剝離することが重要で、この層で剝離を進めれば尿管や精巣（卵巣）動・静脈は腎筋膜の背側にあるので損傷することはない。腰部交感神経および上下腹神経叢は自然に温存される。

S状結腸を左側へ牽引し、右総腸骨動脈上縁から十二指腸水平部に向かって小腸とS状結腸間膜の移行部で後腹膜を切開、下腸間膜動脈根部を確認して、大動脈の外膜を露出し、周囲脂肪組織を根部に付けて下腸管膜動脈を根部で二重結紮・切離する（図2b）。

留意点：この位置では右側の腰部交感神経は右外側へ離れているので損傷することはないが、左側の腰部交換神経は下腸管膜動脈に密接していることも多く注意する。

脂肪織が乏しい患者では、左腰部交感神経を下腸間膜動脈から遊離しようとする下腸間膜動脈が露出することがある。このような症例では腰部交感神経を切離して下腸間膜動脈を被っている間膜を破らないようにする。リンパ節転移がある場合に同間膜を破れば癌を散布することになる。間膜を破りそうな場合には左腰部交感神経を合併切除することもある。

4. S状結腸間膜およびS状結腸の切離

下腸間膜動脈の切離部位と同じ高さで下腸間膜静脈および左結腸動・静脈を切離する。S状結腸動脈の1枝以上を摘徐直腸側へ付けるよう




図3 直腸の遊離

- a) 直腸固有筋膜に沿って後壁を剥離する。下腹神経は固有筋膜に癒着していることがあるので損傷に注意する。
- b) 直腸後壁で肛門挙筋を露出したら、Metzenbaumを肛門挙筋に沿って外側に矢印の方向へ剥離操作を進め、膀胱下腹筋膜との間を剥離する。
- c) 直腸前壁の剥離が前立腺に到達したら、その腹側・外側にある骨盤神経叢からの臓側枝を損傷しないように直腸壁に沿ってMetzenbaumで挙筋前腔を開放する(右白矢印)。挙筋前腔へ長い鉤を入れて側方靭帯を遊離し、骨盤神経叢を温存して切離する(左黒矢印)。

後壁)を剥離する。

留意点：骨盤内直腸の剥離には各種の幅および長さの鉤を使い分けて、術野を展開し、操作する部位を直接視認することが肝要である。

直腸切断術で出血が多いのは、会陰操作で皮切を行ってから直腸を摘出するまでの間であり、腹腔側から肛門挙筋まで直腸を十分に遊離しておくことが会陰操作の時間を短くして出血を少なくするコツである。

6. 会陰操作

a) 体位

股関節を強く屈曲した碎石位とし、会陰部を十分に手術台から外にはみ出させておく。陰嚢は上方へ吊り上げて絆創膏で固定する。

留意点：臀部、肛門部の皮膚がピンと張った状態にすることが切離操作、視野の展開に重要である。

b) 皮切

肛門を巾着縫合(1-0絹糸)で閉鎖してから、前方は浅会陰横筋上、左右側方は両側坐骨結節のやや内側寄り、背側は尾骨上に肛門を中心に楕円状の皮膚切開をおく(図4)。




図 4 会陰皮膚切開




図 5 下直腸動・静脈の切離と座骨直腸窩の郭清

留意点:切断術後の会陰創は、臀裂がなくなつて進展・緊張し、座ったり前屈したりする時に創が引っ張られて痛い。この創の進展・緊張を少なくするために皮切は頭尾側への精円状とし、また腫瘍が肛門管から離れていれば小さくする。

皮下脂肪組織を、前方は浅会陰横筋を越えて、左右側方は両側坐骨結節まで skin flap を作つて電気メスで切離し、大殿筋筋膜を露出する。大殿筋筋膜上の脂肪織を腸管側へ付け、大殿筋内縁に沿って坐骨結節側から尾骨先端まで筋膜を切離し、大殿筋を露出する (図 5)。

留意点: skin flap 作製時には坐骨結節を越えて大腿の筋肉まで露出しないように注意する。

C) 坐骨直腸窩脂肪織の切除郭清

会陰創に鉤の浅い開創器を掛け、直腸を鉤で反対側に牽引し、恥骨弓内縁に沿って坐骨直腸窩の脂肪組織を Metzenbaum で肛門側へ切離して、下直腸動・静脈および内会陰動・静脈からの直腸枝を露出し、起始部で切離する。肛門挙筋の背側 2/3 を露出する。

留意点: 坐骨直腸窩の脂肪組織の切離に際しては、Metzenbaum をやさしく扱って血管、とくに静脈を破綻しないようにする。注意して操作すれば損傷して出血するようなことはな




図 6 肛門挙筋の切離

い。いったん静脈を切断してしまうと、静脈は筋肉内に埋没してしまい、止血に難渋する。

d) 肛門挙筋の切離と直腸切断

両側方の肛門挙筋が露出できたら尾骨直腸靭帯を電気メスで切離し、腹腔側から切離展開してきた骨盤腔と連絡する。左示指を骨盤腔内へ挿入し、肛門挙筋付着部を確認しながら骨盤付着部で直視下に電気メスで切離を進める (図 6)。肛門挙筋の背側 2/3 を切離したら直腸を肛門側腹腔外へ脱転させ、直腸を前方へ牽引し